TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01131026
Drug: Amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tablet, 1000 mg, once a day for ten days
Study: NCT01131026
Drug: Lansoprazole
Normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: capsule, 30 mg, twice a day for ten days
Study: NCT00648804
Drug: Ondansetron Orally Disintegrating Tablets 8 mg
Normalized name: ondansetron Disintegrating Oral Tablet
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8mg, single dose fed
Study: NCT03287050
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg IV q 21 days
Study: NCT00182819
Drug: temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles
Study: NCT03661775
Drug: Magnesium sulfate administration
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: controlled group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2 grams for maintenance dose per hour Experimental group : administration of magnesium sulfate is 4 grams for loading dose in 15 minutes, followed by 2.5 grams for maintenance dose per hour
Study: NCT02916927
Drug: Ketamine IV Infusion
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 0.3 mg/kg in 100mL normal saline minibag administered over 15 min and placebo 10 mL normal saline syringe administered over 1 minute.
Study: NCT02916927
Drug: Ketamine IV push
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ketamine 0.3 mg/kg in 10 mL normal saline syringe administered over 1 minute and placebo 100mL normal saline minibag administered over 15 min.
Study: NCT00489203
Drug: beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given orally
Study: NCT00489203
Drug: tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given after transplant
Study: NCT02377336
Drug: GS-6615
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: GS-6615 tablets administered orally
Study: NCT02702960
Drug: Mesna
Normalized name: Mesna
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: administered on Days 3 and 4 with PTCy
Study: NCT02702960
Drug: Filgrastim
Normalized name: Filgrastim
DrugBank: Filgrastim (DB00099)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery
Study: NCT02702960
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
Study: NCT02702960
Drug: mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
Study: NCT02702960
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
Study: NCT02702960
Drug: Antithymocyte globulin
Normalized name: Rabbit antithymocyte globulin
DrugBank: Antithymocyte immunoglobulin (rabbit) (DB00098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0
Study: NCT02702960
Drug: fludarabine
Normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: fludarabine given from Days -6 to Day -2 before BMT
Study: NCT01775592
Drug: Arterakin (DHA-PPQ)
Normalized name: Atexakin alfa
DrugBank: Atexakin alfa (DB19234)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04488575
Drug: EDP1815
Normalized name: EDP1815
DrugBank: EDP1815 (DB16486)
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDP1815 is an orally administered monoclonal microbe
Study: NCT03688230
Drug: abituzumab
Normalized name: Abituzumab
DrugBank: Abituzumab (DB12775)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg IV
Study: NCT02228382
Drug: Bosutinib
Normalized name: Bosutinib
DrugBank: Bosutinib (DB06616)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg and 500 mg tablets, once daily dosage up to 4 years duration
Study: NCT00315874
Drug: Buprenorphine transdermal delivery system
Normalized name: buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02035709
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.
Study: NCT01096927
Drug: Amoxicillin and Clavulanic Acid
Normalized name: Amoxicillin and clavulanic acid only product
DrugBank: Clavulanic acid (DB00766)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
Study: NCT03363295
Drug: Moxifloxacin Injection
Normalized name: moxifloxacin Injection
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: One group will receive moxifloxacin injection (0,03ml) in the anterior chamber by the end of phacoemulsification surgery
Study: NCT00629720
Drug: alfuzosin (SL770499)
DrugBank: Alfuzosin (DB00346)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02639546
Drug: Cobimetinib
Normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
Study: NCT00972881
Drug: irinotecan hydrochloride
Normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00522834
Drug: Elesclomol (STA-4783)
Normalized name: Elesclomol
DrugBank: Elesclomol (DB05719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle. Number of cycles: Until progression or unacceptable toxicity develops
Study: NCT00522834
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 80 mg/m2 paclitaxel alone administered intravenously once a week for the first 3 weeks of a 4 weeks cycle. Number of cycles: Until progression or unacceptable toxicity develops
Study: NCT02258581
Drug: GS-4774
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Exposure of interest for participants who received GS-4774 (administered as a subcutaneous injection) in a previous Gilead study for chronic hepatitis B virus infection.
Study: NCT02258581
Drug: GS-9620
Normalized name: GS 9137
DrugBank: Elvitegravir (DB09101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Exposure of interest for participants who received GS-9620 (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
Study: NCT02258581
Drug: Tenofovir disoproxil fumarate (TDF)
Normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exposure of interest for participants who received TDF (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
Study: NCT00858988
Drug: Rifaximin
Normalized name: Rifaximin
DrugBank: Rifaximin (DB01220)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 100mg of rifaxin for 7 consecutive days, twice daily
Study: NCT00944554
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Varenicline given twice a day or five weeks.
Study: NCT01581710
Drug: Montelukast to placebo
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks
Study: NCT03130764
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1500 mg, IV over 1 hour Every 4 weeks for 1 year
Study: NCT03130764
Drug: Tremelimumab
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg, IV over 1 hour Every 4 weeks for 4 doses
Study: NCT02600260
Drug: Enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.
Study: NCT00265733
Drug: paclitaxel poliglumex
Normalized name: PACLITAXEL POLIGLUMEX
DrugBank: Paclitaxel poliglumex (DB13809)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00262379
Drug: epoetin beta (NeoRecormon®)
Normalized name: Epoetin beta
DrugBank: Epoetin beta (DB19434)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: • Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
Study: NCT01349595
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients randomized to bortezomib treatment will receive 2, 4-dose cycles of drug followed by a 2 month hiatus. At the end of this time, subjects will be re-evaluated for the appropriateness of receiving a 3rd and 4th cycle of bortezomib. Bortezomib will be given subcutaneously (under the skin). If unable to give subcutaneously, bortezomib will be given as a single IV (injection into vein) over a time of 3 to 5 seconds. Patients will receive up to 4, four-dose cycles of 1.3 mg/m(2) (based on body surface area).
Study: NCT00337883
Drug: Erlotinib HCl (OSI-774)
Normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01581710
Drug: Placebo to montelukast
DrugBank: Montelukast (DB00471)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will receive matching placebo. Each treatment period consists of 2 weeks
Study: NCT00928083
Drug: OZ439 50mg API capsules
Normalized name: API
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00358423
Drug: Pegaptanib Sodium
Normalized name: Pegaptanib Sodium
DrugBank: Pegaptanib (DB04895)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections
Study: NCT00358423
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sham injections, every 6 weeks, up to a total of 3 sham injections
Study: NCT03993132
Drug: Empagliflozin
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: new users (initiators) of Empagliflozin
Study: NCT03993132
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: initiators of Liraglutide
Study: NCT01880619
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this arm will receive Tamsulosin 0.4 mg daily
Study: NCT01880619
Drug: Solifenacin
Normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in the arm will receive Solifenacin
Study: NCT01880619
Drug: Control
Normalized name: Control
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients in this are will receive placebo
Study: NCT01034189
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3\~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
Study: NCT01034189
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
Study: NCT01034189
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
Study: NCT00928083
Drug: OZ439 200mg API capsules
Normalized name: API
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00960427
Drug: systemic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02402062
Drug: TH-302 + Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle.
Study: NCT01577914
Drug: Carvedilol Tablets USP 12.5 mg
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5mg tablet once a day
Study: NCT01577914
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12.5mg tablet once a day
Study: NCT01937299
Drug: Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension
DrugBank: Brimonidine (DB00484)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01937299
Drug: Travoprost 0.004% ophthalmic solution
Normalized name: Travoprost 0.004% Ophthalmic Solution
DrugBank: Travoprost (DB00287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT01550926
Drug: 120 mg orlistat
Normalized name: orlistat 120 MG
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 X60 mg capsule
Study: NCT01550926
Drug: 60 mg orlistat
Normalized name: orlistat 60 MG
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg orlistat
Study: NCT01550926
Drug: orlistat experimental dose
Normalized name: Orlistat
DrugBank: Orlistat (DB01083)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: experimental
Study: NCT00928083
Drug: OZ439 100mg API capsules
Normalized name: API
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 100mg (2x50mg API capsules)
Study: NCT00928083
Drug: OZ439 400mg API capsules
Normalized name: API
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 400mg (2x200mg API capsules)
Study: NCT00091858
Drug: Darbepoetin Alfa
Normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6.75 mcg/kg Q4W
Study: NCT03167918
Drug: metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: gave each patient 1000 mg, bid, PO
Study: NCT03167918
Drug: Mecobalamin Tablets
Normalized name: mecobalamin Oral Tablet
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: gave each patient 0.5 mg bid, PO
Study: NCT00928083
Drug: OZ439 800mg API capsules
Normalized name: API
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 800mg (4x200 API capsules)
Study: NCT00928083
Drug: OZ439 1200mg API capsules
Normalized name: API
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OZ439 1200mg (6x200mg API capsules)
Study: NCT00153283
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00099528
Drug: REN-1654
Normalized name: Ren shen
DrugBank: Ginseng (DB01404)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00219297
Drug: Patupilone
Normalized name: Patupilone
DrugBank: Patupilone (DB03010)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00039611
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04502069
Drug: Opaganib
Normalized name: Opaganib
DrugBank: Opaganib (DB12764)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg Q12 hours orally
Study: NCT04217720
Drug: SNS-301
Normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SNS-301 (1x 1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.
Study: NCT00724568
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
Study: NCT00724568
Drug: Bortezomib
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
Study: NCT00724568
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
Study: NCT00724568
Drug: Doxil
Normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will be treated with Doxil on day 4.
Study: NCT00520741
Drug: Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.
Study: NCT00520741
Drug: Lacosamide
Normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
Study: NCT00999869
Drug: Botulinum toxin type A
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
Study: NCT01206166
Drug: Olimel (5.7%E / N9E)
Normalized name: vitamin E 5 UNT
DrugBank: Lime (citrus) (DB10635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
Study: NCT00999869
Drug: Triamcinolone acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
Study: NCT02532764
Drug: QR-010
Normalized name: mannitol
DrugBank: Mannitol (DB00742)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
Study: NCT01683175
Drug: Erlotinib
Normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01683175
Drug: cis-platinum
Normalized name: cis-Platinum
DrugBank: Platinum (DB12257)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01683175
Drug: Vinorelbine
Normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03103100
Drug: 1% Lidocaine
Normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mL of 1% lidocaine
Study: NCT03103100
Drug: 0.25% Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mL of 0.25% bupivacaine
Study: NCT03103100
Drug: Bupivacaine plus Lidocaine
Normalized name: bupivacaine / lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
Study: NCT00531206
Drug: Tipranavir
Normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00531206
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: low dose
Study: NCT03463512
Drug: Racecadotril plus ORS
DrugBank: Racecadotril (DB11696)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Racecadotril plus ORS
Study: NCT03463512
Drug: ORS
Normalized name: HORSE
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORS
Study: NCT00003399
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003399
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003399
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003399
Drug: etoposide
Normalized name: Etoposide
DrugBank: Etoposide (DB00773)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003399
Drug: melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00003399
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT03823300
Drug: Faricimab
Normalized name: Faricimab
DrugBank: Faricimab (DB15303)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Faricimab will be administered by intravitreal injection into the study eye at intervals as specified in the study protocol.
Study: NCT03823300
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Aflibercept will be administered by intravitreal injection into the study eye once every 4 weeks for 3 consecutive months, followed by once every 8 weeks (Q8W).
Study: NCT01695109
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: sc injections of 0.6 mg Liraglutide daily for three continuous days.
Study: NCT03505853
Drug: Givosiran
Normalized name: Givosiran
DrugBank: Givosiran (DB15066)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: single dose of givosiran by subcutaneous (sc) injection
Study: NCT03505853
Drug: 5-probe cocktail
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan